IVACC — Intervacc AB Share News
0.000.00%
Last trade - 00:00- SEK443.06m
- SEK297.43m
- SEK20.09m
Brief: Intervacc: Positive Results From Strangvac Clinical Trials Published In Scientific Journal Vaccine
Brief: Intervacc Q1 Operating Loss Widens To SEK 6.3 Million
Brief: Intervacc Awarded Funding From Vinnova For Further Development Of Vaccine Against Staphylococcus Aureus Infections
Brief: Intervacc Says EMA Confirmed That Co's Application For Granting Of A Community Marketing Authorization For Strangvac Is Complete
Brief: Intervacc Q4 Operating Loss Widens To SEK 7.8 Million
Brief: Intervacc Appoints Jan Persson As New CFO
Brief: Intervacc Q3 Operating Loss At SEK 6.2 Million
Brief: Intervacc Says Completed Manufacturing Process For Strangvac
Brief: Intervacc Updates On Strangvac's EMA Application Timeline
Brief: Intervacc Says Completed Directed Issue To Institutional Investors Of About SEK 62 Mln
Brief: Intervacc Q2 Operating Loss Narrows To SEK 8.4 Mln
Brief: Intervacc Expands Distribution Agreement With Animalcare Group
Brief: Intervacc Sings Contract With Swedish University Of Agricultural Science
Brief: Intervacc Q1 Operating Loss Narrows To SEK 5.4 Mln
Brief: Intervacc AB Q4 EBITDA Loss At SEK 5.3 Million
Brief: Intervacc Appoints New CEO
Brief: Intervacc Q3 EBITDA Loss Widens To SEK 4.5 Million
Brief: Intervacc Q2 EBITDA Loss Sek 2.3 Million
Brief: Intervacc Recieves Funding From Eurostars For Further Development Of Vaccine For Piglets.